Dtsch Med Wochenschr 2014; 139(31/32): 1572-1575
DOI: 10.1055/s-0034-1370168
Hämatologie & Onkologie | Commentary
Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelles zur systemischen Mastozytose

Systemic Mastocytosis
G. Metzgeroth
1   III. Medizinische Klinik, Hämatologie und internistische Onkologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg
,
J. Schwaab
1   III. Medizinische Klinik, Hämatologie und internistische Onkologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg
,
A. Reiter
1   III. Medizinische Klinik, Hämatologie und internistische Onkologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg
› Author Affiliations
Further Information

Publication History

Publication Date:
30 July 2014 (online)

    Permissions and Reprints

Schlüsselwörter

Systemische Mastozytose - Mastzellerkrankungen

Keywords

systemic mastocytosis - mast cell disease
 

  • Literatur

  • 1 Damaj G, Joris M et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014; 9: e85362
    CrossrefGoogle Scholar
  • 2 Erben P, Schwaab J et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81-88
    CrossrefGoogle Scholar
  • 3 Georgin-Lavialle S, Lhermitte L et al. Mast cell leukemia. Blood 2013; 121: 1285-1295
    CrossrefGoogle Scholar
  • 4 Gotlib J, Pardanani A et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393-2401
    CrossrefGoogle Scholar
  • 5 Gotlib J, Kluin-Nelemans HC et al. Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): Updated stage 1 results of the Global D2201 Trial. ASH Annual Meeting Abstracts; 2013. Abstract 106
    Google Scholar
  • 6 Hanssens K, Brenet F et al. SRSF2-P95 Hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica 2014; 99: 830-835
    CrossrefGoogle Scholar
  • 7 Hoermann G, Gleixner KV et al. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy 2014; 69: 810-813
    CrossrefGoogle Scholar
  • 8 Kristensen T, Broesby-Olsen S et al. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol 2012; 89: 42-46
    CrossrefGoogle Scholar
  • 9 Kristensen T, Broesby-Olsen S et al. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. Eur J Haematol 2013; 91: 106-111
    CrossrefGoogle Scholar
  • 10 Kristensen T, Vestergaard H et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014; 89: 493-498
    CrossrefGoogle Scholar
  • 11 Morgado JM, Sanchez-Munoz L et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012; 25: 516-521
    CrossrefGoogle Scholar
  • 12 Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 2013; 121: 3085-3094
    CrossrefGoogle Scholar
  • 13 Pardanani A. Systemic mastocytosis in adults. Am J Hematol 2013; 88: 612-624
    CrossrefGoogle Scholar
  • 14 Pardanani A, Finke C et al. Increased circulating IL-2R alpha (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis. Leukemia 2013; 27: 1430-1433
    CrossrefGoogle Scholar
  • 15 Schwaab J, Schnittger S et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460-2466
    CrossrefGoogle Scholar
  • 16 Soucie E, Hanssens K et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 2012; 120 (24) 4846-4849
    CrossrefGoogle Scholar
  • 17 Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 2012; 5: 261-274
    CrossrefGoogle Scholar
  • 18 Swerdlow SH, Harris NL. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: International Agency for Research and Cancer (IARC); 2008
    Google Scholar
  • 19 Teodosio C, Garcia-Montero AC et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012; 26: 951-958
    CrossrefGoogle Scholar
  • 20 Ustun C, Reiter A et al. Hematopoietic stem cell transplantation for advanced systemic mastocytosis. JCO 2014; JCO/2014/552018 in press.
    Google Scholar
  • 21 Valent P. Mastocytosis. Am J Cancer Res 2013; 3: 159-172
    Google Scholar
  • 22 Valent P, Aberer E et al. Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis. Am J Blood Res 2013; 3: 174-180
    Google Scholar
  • 23 Valent P, Escribano L et al. Proposed diagnostic algorithm for patients with suspected mastocytosis. Allergy 2014; May 19 [Epub ahead of print] DOI: 10.1111/all.12436.
    Google Scholar
  • 24 Valent P, Sotlar K et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML). Ann Oncol 2014; Mar 27. [Epub ahead of print]
    Google Scholar